Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Carna Biosciences Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units, indicating some technical concentration within the portfolio. The prosecution involves 3 distinct examiners, meaning each of the 3 pending office actions is being reviewed by a different individual.
MOU, LIYUAN is the busiest examiner for the company, currently holding 1 pending office action. The involvement of 3 distinct examiners for 3 pending office actions means that no single examiner has a dominant influence over the current portfolio. However, the concentration in 2 distinct art units suggests that the company's pharmaceutical innovations fall into a few specific technical categories.
For practitioners, this distribution requires managing 3 separate examiner relationships while navigating the standards of 2 distinct art units. The 1 to 1 ratio of pending office actions to distinct examiners ensures that each case receives an independent review. The focus on 2 distinct art units provides a slightly more concentrated technical landscape compared to a fully diversified portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| BARSKY, JARED | 1 | 50.3% | +22.8% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17796814 | ANTICANCER AGENT COMPOSITION | INAM, SAHAR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836495 | FLUOROISOQUINOLINE COMPOUND AND PRODUCTION METHOD THEREOF | MOU, LIYUAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035592 | COMBINATION PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD | BARSKY, JARED | 84d |
| 18836495 | FLUOROISOQUINOLINE COMPOUND AND PRODUCTION METHOD THEREOF | MOU, LIYUAN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836495 | FLUOROISOQUINOLINE COMPOUND AND PRODUCTION METHOD THEREOF | MOU, LIYUAN | 1628 | §103§112 | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18035592 | COMBINATION PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD | BARSKY, JARED | 1628 | §103Other | Final Rejection | 84d | Pending | May 05, 2023 |
| 17796814 | ANTICANCER AGENT COMPOSITION | INAM, SAHAR | 1622 | §103 | Final Rejection | — | Pending | Aug 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCarna Biosciences Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Liyuan Mou has the most, with 1 of Carna Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
